Cephalon Offers $231 Million Takeover of ChemGenex

Cephalon has offered to buy the Australian company ChemGenex Pharmaceuticals for about $231 million, or 225 Australian dollars.

Cephalon's bid "has the unanimous support of the ChemGenex directors," who plan to recommend it to shareholders unless a better offer appears, the companies said in a statement on Monday.

The all-cash bid of 70 Australian cents per share represents a 59 percent premium to the last traded price of ChemGenex shares.

Cephalon also is offering 2 Australian cents for every Australian Securities Exchange-listed ChemGenex option.

The Australian company is seeking Food and Drug Administration approval to sell the injectable drug Omapro in the United States for chronic myeloid leukemia patients with a specific genetic mutation.

Cephalon in December signed a major partnership deal with Australia's Mesoblast Ltd for a variety of potential therapies in cardiovascular and neurological areas, and it also bought a 20 percent stake in the company.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.